与 S2 结合的α1-酸糖蛋白的升高与慢性丙型肝炎病毒感染和肝细胞癌有关

IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Carlos Oltmanns, Birgit Bremer, Laura Kusche, Per Stål, Robin Zenlander, Jan Tauwaldt, Ingvar Rydén, Peter Påhlsson, Markus Cornberg, Heiner Wedemeyer
{"title":"与 S2 结合的α1-酸糖蛋白的升高与慢性丙型肝炎病毒感染和肝细胞癌有关","authors":"Carlos Oltmanns,&nbsp;Birgit Bremer,&nbsp;Laura Kusche,&nbsp;Per Stål,&nbsp;Robin Zenlander,&nbsp;Jan Tauwaldt,&nbsp;Ingvar Rydén,&nbsp;Peter Påhlsson,&nbsp;Markus Cornberg,&nbsp;Heiner Wedemeyer","doi":"10.1111/jvh.13943","DOIUrl":null,"url":null,"abstract":"<p>There is an urgent need for new high-quality markers for the early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2-bound α1-acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2-bound AGP in the early detection of HCC. In a retrospective case–control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct-acting antiviral agents (<i>n</i> = 93), we measured S2-bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at the start of treatment, end of treatment and follow-up (maximum: 78 months). Patients were retrospectively propensity score matched (1:2). Thirty-one patients chronically infected with HCV developed HCC after a sustained virological response, while 62 did not. In addition, samples of patients with chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease and HCC of different etiologies were analysed. S2-bound AGP elevation in HCC patients was confirmed. However, we did not observe a predictive advantage of S2-bound AGP for the early detection of HCC during treatment and follow-up. Interestingly, S2-bound AGP levels correlated with aspartate aminotransferase (ρ = .56, <i>p</i> = 9.5×10<sup>−15</sup>) and liver elastography (ρ = .67, <i>p</i> = 2.2×10<sup>−16</sup>). Of note, S2-bound AGP decreased in patients chronically infected with HCV after treatment-induced HCV clearance. Fucosylated S2-bound AGP levels were elevated in patients with chronic HCV and HCC. The potential role of S2-bound AGP as a novel tumour marker requires further investigation.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 7","pages":"383-390"},"PeriodicalIF":2.5000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.13943","citationCount":"0","resultStr":"{\"title\":\"Elevation of S2-bound α1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma\",\"authors\":\"Carlos Oltmanns,&nbsp;Birgit Bremer,&nbsp;Laura Kusche,&nbsp;Per Stål,&nbsp;Robin Zenlander,&nbsp;Jan Tauwaldt,&nbsp;Ingvar Rydén,&nbsp;Peter Påhlsson,&nbsp;Markus Cornberg,&nbsp;Heiner Wedemeyer\",\"doi\":\"10.1111/jvh.13943\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>There is an urgent need for new high-quality markers for the early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2-bound α1-acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2-bound AGP in the early detection of HCC. In a retrospective case–control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct-acting antiviral agents (<i>n</i> = 93), we measured S2-bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at the start of treatment, end of treatment and follow-up (maximum: 78 months). Patients were retrospectively propensity score matched (1:2). Thirty-one patients chronically infected with HCV developed HCC after a sustained virological response, while 62 did not. In addition, samples of patients with chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease and HCC of different etiologies were analysed. S2-bound AGP elevation in HCC patients was confirmed. However, we did not observe a predictive advantage of S2-bound AGP for the early detection of HCC during treatment and follow-up. Interestingly, S2-bound AGP levels correlated with aspartate aminotransferase (ρ = .56, <i>p</i> = 9.5×10<sup>−15</sup>) and liver elastography (ρ = .67, <i>p</i> = 2.2×10<sup>−16</sup>). Of note, S2-bound AGP decreased in patients chronically infected with HCV after treatment-induced HCV clearance. Fucosylated S2-bound AGP levels were elevated in patients with chronic HCV and HCC. The potential role of S2-bound AGP as a novel tumour marker requires further investigation.</p>\",\"PeriodicalId\":17762,\"journal\":{\"name\":\"Journal of Viral Hepatitis\",\"volume\":\"31 7\",\"pages\":\"383-390\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-04-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.13943\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Viral Hepatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvh.13943\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Viral Hepatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvh.13943","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目前迫切需要新的高质量标记物来早期检测肝细胞癌(HCC)。Åström等人认为,S2结合的α1-酸糖蛋白(AGP)可能是一种有前景的标记物。因此,我们评估了 S2 结合型 AGP 在早期检测 HCC 中的预测优势。在一项针对接受直接作用抗病毒药物治疗的慢性丙型肝炎病毒(HCV)感染患者(n = 93)的回顾性病例对照研究中,我们使用 HepaCheC® ELISA 试剂盒(Glycobond AB,Linköping,SE)在治疗开始、治疗结束和随访(最长 78 个月)时测量了 S2 结合型 AGP。对患者进行回顾性倾向评分匹配(1:2)。31例慢性丙型肝炎病毒感染者在持续病毒学应答后发展为HCC,62例未发展为HCC。此外,还分析了慢性乙型肝炎病毒感染、代谢功能障碍相关性脂肪性肝病和不同病因导致的 HCC 患者样本。结果证实,HCC 患者的 S2 结合型 AGP 升高。但是,在治疗和随访过程中,我们并未发现 S2 结合 AGP 对早期发现 HCC 有预测优势。有趣的是,S2-结合AGP水平与天冬氨酸氨基转移酶(ρ = .56,p = 9.5×10-15)和肝脏弹性成像(ρ = .67,p = 2.2×10-16)相关。值得注意的是,慢性感染 HCV 的患者在接受治疗诱导 HCV 清除后,S2 结合的 AGP 会减少。慢性 HCV 和 HCC 患者的岩藻糖基化 S2 结合型 AGP 水平升高。S2-结合AGP作为一种新型肿瘤标志物的潜在作用需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Elevation of S2-bound α1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma

Elevation of S2-bound α1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma

There is an urgent need for new high-quality markers for the early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2-bound α1-acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2-bound AGP in the early detection of HCC. In a retrospective case–control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct-acting antiviral agents (n = 93), we measured S2-bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at the start of treatment, end of treatment and follow-up (maximum: 78 months). Patients were retrospectively propensity score matched (1:2). Thirty-one patients chronically infected with HCV developed HCC after a sustained virological response, while 62 did not. In addition, samples of patients with chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease and HCC of different etiologies were analysed. S2-bound AGP elevation in HCC patients was confirmed. However, we did not observe a predictive advantage of S2-bound AGP for the early detection of HCC during treatment and follow-up. Interestingly, S2-bound AGP levels correlated with aspartate aminotransferase (ρ = .56, p = 9.5×10−15) and liver elastography (ρ = .67, p = 2.2×10−16). Of note, S2-bound AGP decreased in patients chronically infected with HCV after treatment-induced HCV clearance. Fucosylated S2-bound AGP levels were elevated in patients with chronic HCV and HCC. The potential role of S2-bound AGP as a novel tumour marker requires further investigation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Viral Hepatitis
Journal of Viral Hepatitis 医学-病毒学
CiteScore
6.00
自引率
8.00%
发文量
138
审稿时长
1.5 months
期刊介绍: The Journal of Viral Hepatitis publishes reviews, original work (full papers) and short, rapid communications in the area of viral hepatitis. It solicits these articles from epidemiologists, clinicians, pathologists, virologists and specialists in transfusion medicine working in the field, thereby bringing together in a single journal the important issues in this expanding speciality. The Journal of Viral Hepatitis is a monthly journal, publishing reviews, original work (full papers) and short rapid communications in the area of viral hepatitis. It brings together in a single journal important issues in this rapidly expanding speciality including articles from: virologists; epidemiologists; clinicians; pathologists; specialists in transfusion medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信